Imatinib and the treatment of fibrosis: Recent trials and tribulations

Current Rheumatology Reports

Volumn 13, Issue 1, 2011, Pages 51-58

  Gordon, Jessica ^a   Spiera, Robert ^a  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

Author keywords

Fibrosis; Imatinib; Scleroderma; Systemic sclerosis; Tyrosine kinase inhibitor

Indexed keywords

ABELSON KINASE; CONNECTIVE TISSUE GROWTH FACTOR; CYCLOPHOSPHAMIDE; DIURETIC AGENT; GADOLINIUM; IMATINIB; METHOTREXATE; PLACEBO; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; SMAD1 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ALOPECIA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; BONE METABOLISM; CARDIOTOXICITY; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DIARRHEA; DIASTOLIC DYSFUNCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; EROSIVE GASTRITIS; FATIGUE; FIBROGENESIS; FIBROSING ALVEOLITIS; FIBROSIS; FLUID RETENTION; FORCED VITAL CAPACITY; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GENERALIZED EDEMA; HUMAN; HYPOPHOSPHATEMIA; HYPOTHYROIDISM; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FIBROSIS; LIVER FIBROSIS; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; MINERAL METABOLISM; MUSCLE CRAMP; MYALGIA; MYOFIBROBLAST; NAUSEA; NEPHROGENIC SYSTEMIC FIBROSIS; NEUTROPENIA; NONHUMAN; PERICARDIAL EFFUSION; PERIORBITAL EDEMA; PLEURA EFFUSION; POLYOMAVIRUS INFECTION; PULMONARY HYPERTENSION; SIDE EFFECT; SKIN BIOPSY; SKIN FIBROSIS; STOMACH ANTRUM VASCULAR ECTASIA; SYSTEMIC SCLEROSIS; THORAX PAIN; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEAKNESS;

FIBROSIS; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SCLERODERMA, SYSTEMIC;

EID: 79551573507     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-010-0146-6     Document Type: Article

References (50)

1. J Varga D Abraham 2007 Systemic sclerosis: a prototypic multisystem fibrotic disorder J Clin Invest 117 557 567 1:CAS:528:DC%2BD2sXis12htrw%3D 10.1172/JCI31139 17332883 (Pubitemid 46348510)
2. AJ Tyndall B Bannert M Vonk, et al. 2010 Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Ann Rheum Dis 69 1809 1815 10.1136/ard.2009.114264 20551155
3. NP Quillinan CP Denton 2009 Disease-modifying treatment in systemic sclerosis: current status Curr Opin Rheumatol 21 636 641 10.1097/BOR. 0b013e3283310d57 19726995
4. SI Nihtyanova EC Tang JG Coghlan, et al. 2010 Improved survival in systemic sclerosis is associated with better ascertainment of internal organ disease: a retrospective cohort study QJM 103 109 115 1:STN:280: DC%2BC3c%2FktFWitQ%3D%3D 10.1093/qjmed/hcp174 19966313
5. PJ Clements PA Lachenbruch JR Seibold, et al. 1993 Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies J Rheumatol 20 1892 1896 1:STN:280:DyaK2c7ktFOqsw%3D%3D 8308774
6. TA Medsger 2003 Natural history of systemic sclerosis and the assessment of disease activity, severity, functional status, and psychologic well-being Rheum Dis Clin North Am 29 255 273 10.1016/S0889-857X(03)00023-1 12841294
7. S Amjadi P Maranian DE Furst, et al. 2009 Course of the modified Rodnan skin thickness score in systemic sclerosis clinical trials: analysis of three large multicenter, double-blind, randomized controlled trials Arthritis Rheum 60 2490 2498 10.1002/art.24681 19644851
8. AL Herrick M Lunt N Whidby, et al. 2010 Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis J Rheumatol 37 116 124 10.3899/jrheum.090668 19955050
9. JA Varga M Trojanowska 2008 Fibrosis in systemic sclerosis Rheum Dis Clin North Am 34 115 143 10.1016/j.rdc.2007.11.002 18329536 (Pubitemid 351329455)
10. J Rosenbloom SV Castro SA Jimenez 2010 Narrative review: fibrotic diseases: cellular and molecular mechanisms and novel therapies Ann Intern Med 152 159 166 20124232
11. H Higley K Persichitte S Chu, et al. 1994 Immunocytochemical localization and serologic detection of transforming growth factor beta 1: association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon Arthritis Rheum 37 278 288 1:STN:280:DyaK2c7nsF2ksg%3D%3D 10.1002/art.1780370218 7510487
12. A Ludwicka T Ohba M Trojanowska, et al. 1995 Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma J Rheumatol 22 1876 1883 1:CAS:528:DyaK2MXpsVWjsbY%3D 8991985
13. L Klareskog R Gustafsson A Scheynius, et al. 1990 Increased expression of platelet-derived growth factor type B receptors in the skin of patients with systemic sclerosis Arthritis Rheum 33 1534 1541 1:STN:280:DyaK3M%2FisFWmtw%3D%3D 10.1002/art.1780331011 2171541
14. SS Baroni M Santillo F Bevilacqua, et al. 2006 Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis N Engl J Med 354 2667 2676 1:CAS:528:DC%2BD28XmtFSgtLg%3D 10.1056/NEJMoa052955 16790699
15. D Dragun JH Distler G Riemekasten O Distler 2009 Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: what functional autoimmunity could learn from receptor biology Arthritis Rheum 60 907 911 10.1002/art.24364 19333918
16. RJ Barst 2005 PDGF signaling in pulmonary arterial hypertension J Clin Invest 115 2691 2694 1:CAS:528:DC%2BD2MXhtVygt7jL 10.1172/JCI26593 16200204 (Pubitemid 41434394)
17. J Massague J Seoane D Wotton 2005 Smad transcription factors. Genes Dev 19 2783 2810 1:CAS:528:DC%2BD2MXhtlWqsrnI
18. S Bhattacharyya W Ishida M Wu, et al. 2009 A non-Smad mechanism of fibroblast activation by transforming growth factor-b via c-Abl and Egr-1: selective modulation by imatinib mesylate Oncogene 28 1285 1297 1:CAS:528:DC%2BD1MXntFCqtQ%3D%3D 10.1038/onc.2008.479 19151753
19. J Pannu Y Asano S Nakerakanti, et al. 2008 Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate Arthritis Rheum 58 2528 2537 1:CAS:528:DC%2BD1cXhtVCjur7P 10.1002/art.23698 18668566
20. SA Jimenez S Gaidarova B Saitta, et al. 2001 Role of protein kinase S-delta in the regulation of collagen gene expression in scleroderma fibroblasts J Clin Invest 108 1395 1403 1:CAS:528:DC%2BD3MXot12ktbc%3D 11696585
21. Y Chen A Leask DJ Abraham, et al. 2008 Heparan sulfate-dependent ERK activation contributes to the overexpression of fibrotic proteins and enhanced contraction by scleroderma fibroblasts Arthritis Rheum 58 577 585 1:CAS:528:DC%2BD1cXivFahtL4%3D 10.1002/art.23146 18240216 (Pubitemid 351294894)
22. JH Distler A Jungel LC Huber, et al. 2007 Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis Arthritis Rheum 56 311 322 1:CAS:528:DC%2BD2sXhsFaisL4%3D 10.1002/art.22314 17195235 (Pubitemid 46106205)
23. A Akhmetshina P Venalis C Dees, et al. 2009 Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis Arthritis Rheum 60 219 224 1:CAS:528:DC%2BD1MXhvFCjsr4%3D 10.1002/art.24186 19116940
24. A Akhmetshina C Dees M Pileckyte, et al. 2008 Dual inhibition of c-Abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis FASEB J 22 2214 2222 1:CAS:528:DC%2BD1cXotlanurg%3D 10.1096/fj.07-105627 18326784 (Pubitemid 351948641)
25. M Li A Abdollahi HJ Grone, et al. 2009 Late treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model Radiat Oncol 4 66 10.1186/1748-717X-4-66 20025728
26. H Yoshiji R Noguchi S Kuriyama, et al. 2005 Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats Am J Physiol Gastrointest Liver Physiol 288 G907 G913 1:CAS:528:DC%2BD2MXktlSnsL8%3D 10.1152/ajpgi.00420.2004 15618280 (Pubitemid 40563130)
27. S Wang MC Wilkes EB Leof, et al. 2010 Noncanonical TGF-beta pathways, mTORC1 and Abl, in renal interstitial fibrogenesis Am J Physiol Renal Physiol 298 F142 F149 1:CAS:528:DC%2BC3cXhsFKlur4%3D 10.1152/ajprenal.00320.2009 19846571
28. B Maurer J Stanczyk A Jüngel, et al. 2010 MicroRNA-29, a key regulator of collagen expression in systemic sclerosis Arthritis Rheum 62 1733 1743 1:CAS:528:DC%2BC3cXhtFGmsr7F 10.1002/art.27443 20201077
29. J Kay W High 2008 Imatinib mesylate treatment of nephrogenic systemic fibrosis Arthritis Rheum 58 2543 2548 1:CAS:528:DC%2BD1cXhtVCjur7J 10.1002/art.23696 18668587
30. A Olivieri F Locatelli M Zecco, et al. 2009 Imatinib for refractory chronic graft-versus-host disease with fibrotic features Blood 114 709 718 1:CAS:528:DC%2BD1MXpt1Wmt7s%3D 10.1182/blood-2009-02-204156 19403889
31. CE Daniels MW Wilkes M Edens, et al. 2004 Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin mediated lung fibrosis J Clin Invest 114 1308 1316 1:CAS:528:DC%2BD2cXpsFCgtrg%3D 15520863
32. CE Daniels JA Lasky AH Limper, et al. 2010 Imatinib treatment for IPF: randomized placebo controlled trial results Am J Respir Crit Care Med 181 604 610 1:CAS:528:DC%2BC3cXhtFahsLfL 10.1164/rccm.200906-0964OC 20007927
33. MH Cohen G Williams JR Johnson, et al. 2002 Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia Clin Cancer Res 8 935 942 1:CAS:528:DC%2BD38XksVSqtbs%3D 12006504
34. R Dagher M Cohen G Williams, et al. 2002 Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors Clin Cancer Res 8 3034 3038 1:CAS:528: DC%2BD38XosFKiu7k%3D 12374669
35. R Kerkelä L Grazette R Yacobi, et al. 2006 Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nat Med 12 908 916 10.1038/nm1446 16862153 (Pubitemid 44175142)
36. E Atallah JB Durand H Kantarjian, et al. 2007 Congestive heart failure is a rare event in patients receiving imatinib therapy Blood 110 1233 1237 1:CAS:528:DC%2BD2sXptFKlsrs%3D 10.1182/blood-2007-01-070144 17449798 (Pubitemid 47281421)
37. E Berman M Nicolaides RG Maki, et al. 2006 Altered bone and mineral metabolism in patients receiving imatinib mesylate N Engl J Med 354 2006 2013 1:CAS:528:DC%2BD28XksFGhs7s%3D 10.1056/NEJMoa051140 16687713
38. JK Gordon SK Magid RG Maki, et al. 2010 Elevations in creatine kinase in patients treated with imatinib mesylate (Gleevec) Leuk Res 34 827 829 1:CAS:528:DC%2BC3cXlt1ans7o%3D 10.1016/j.leukres.2009.11.002 19963273
39. PP Sfikakis VG Gorgoulis CG Katsiari, et al. 2008 Imatinib for the treatment of refractory, diffuse systemic sclerosis Rheumatology (Oxford) 47 735 737 1:CAS:528:DC%2BD1cXkvFymtbc%3D 10.1093/rheumatology/ken104 (Pubitemid 351619226)
40. PLA van Daele WA Dik HB Thio, et al. 2008 Is imatinib mesylate a promising drug in systemic sclerosis? Arthritis Rheum 58 2549 2552 10.1002/art.23648 18668570
41. JH Distler B Manger BM Spriewald, et al. 2008 Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease Arthritis Rheum 58 2538 2542 1:CAS:528: DC%2BD1cXhtVCjur7I 10.1002/art.23694 18668536
42. L Chung DF Fiorentino MJ Benbarak, et al. 2009 Molecular framework for response to imatinib mesylate in systemic sclerosis Arthritis Rheum 60 584 591 1:CAS:528:DC%2BD1MXjt1Cnsrk%3D 10.1002/art.24221 19180499
43. I Sabnani MJ Zucker ED Rosenstein, et al. 2009 A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology 48 49 52 1:CAS:528:DC%2BD1cXhsVOgsLzL 10.1093/rheumatology/ken369 18815156
44. M Hatano A Yao T Shiga, et al. 2010 Imatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertension Int Heart J 51 272 276 1:CAS:528:DC%2BC3cXhtFahsLrJ 10.1536/ihj.51.272 20716845
45. Spiera R, Gordon J, Mersten J, et al.: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a one year, phase IIa, single arm, open label clinical trial [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6-11, 2010.
46. Pope J, McBain DL, Petrlich L, et al.: A proof of concept trial of Gleevec (imatinib) in active diffuse scleroderma (DSSc) [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Philadelphia, PA; October 17-21, 2009.
47. Chung L, Ruiz P, Wood T, et al.: Evaluation of an imatinib response gene signature in patients with systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6-11, 2010.
48. R Saggar D Khanna M Mayes, et al. 2010 Open labeled study of imatinib mesylate (Gleevec) in the treatment of systemic sclerosis-associated active interstitial lung disease (SSc-ILD): preliminary results Am J Respir Crit Care Med 181 A3991
49. Distler O, Distler JHW, Varga J, et al.: A multi-center, open-label, proof of concept study of imatinib mesylate demonstrates no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6-11, 2010.
50. Denton CP, Nihtyanova SI, Varga J, et al.: Comparative analysis of change in modified Rodnan skin score in patients with diffuse systemic sclerosis receiving imatinib mesylate suggests similar disease course to matched patients receiving standard therapy [abstract]. Presented at the American College of Rheumatology Annual Scientific Meeting. Atlanta, GA; November 6-11, 2010.